CBD

Scientists Review State of Cannabis Research in MS

Treatment with cannabis-based medications may ease muscle spasms, decrease pain, and aid in sleep for people with multiple sclerosis (MS), but more research is needed to evaluate the potential benefits of cannabis use. That is the finding of a team of U.S. researchers who published a review paper,Ā “…

Medical Cannabis Lozenges Now Available for MS Patients in Texas

People in Texas with multiple sclerosisĀ (MS) and other medical conditions now have access to cannabis-infused lozenges, Surterra TexasĀ announced. Under a Texas Compassionate Use Program, cannabis-containing therapies may be prescribed to help treat various neurological and other disorders, includingĀ terminal cancer, spasticity,…

Need to Know: Using CBD Topical Products for MS Pain

Editor’s note: “Need to Knowā€ is a series inspired by common forum questions and comments from readers. Have a comment or question about MS? Visit our forum. This week’s question is inspired by the forum post “Need advice about CBD oil,” published on Nov. 1, 2018. Share your…

Atlas Biotechnologies to Fund Research into Cannabis Treatment for MS, Similar Diseases

Atlas BiotechnologiesĀ will fund and provide support to three research projects at the University of AlbertaĀ to possibly identify cannabis component(s) that could help people with neurological diseases likeĀ multiple sclerosis (MS). The cannabis plant produces hundreds of biological compounds, the best-known being tetrahydrocannabinol (THC) ā€” the psychoactive compound primarily…

MMJ Enters Agreement to Produce Cannabis-based Capsules for Clinical Trials in MS and Huntingtonā€™s

MMJ International HoldingsĀ announced that it has entered into an agreement for the production of its proprietary cannabis-based gel capsule ā€” a product mix of tetrahydrocannabinol (THC) and cannabidiol (CBD) ā€” in compliance with guidelines set by the U.S. Food and Drug Administration (FDA) and the Drug Enforcement Administration (DEA).

Phase 1 Clinical Trial of EHP-101 Concludes with Positive Safety Results

The first in-human clinical trial of EHP-101, an investigational treatment for multiple sclerosis (MS) and systemic scleroderma (SSc), has been successfully completed,Ā Emerald Health PharmaceuticalsĀ (EHP) announced. EHP-101 demonstrated it was safe and well-tolerated in healthy volunteers, supporting further clinical development ofĀ EHP-101 in future Phase 2 clinical trials. The…

Medical Marijuana Now Available to MS and Other Patients in Louisiana

Medical cannabis products, jointly developed by GB Sciences Louisiana (GBSL) and the Louisiana State University Agricultural Center‘s (LSU AgCenter)Ā Therapeutic Cannabis Program, are now available for purchase by qualified patients with illnesses that includeĀ multiple sclerosis (MS) at nine state-licensed pharmacies. The decision, announced by the Louisiana Department…

MMJ International Asks FDA to Approve Studies of Cannabis-based Therapies

MMJ International has filed two applications with the U.S. Food and Drug Administration (FDA) requesting permission to begin clinical studies testing its pharmaceutical grade cannabis-based therapies in easing symptoms associated with multiple sclerosis and Huntingtonā€™s disease. ā€œThe filing of these applications with the FDA brings us one step…

Cannabidiol Increases Inflammatory Suppressor Cells, New MS Mouse Study Shows

Non-psychoactiveĀ cannabidiol (CBD), one of the active compounds in medicalĀ cannabis, significantly reduced clinical signs of multiple sclerosis (MS)-like disease in an experimental autoimmune encephalomyelitis mouse model. Researchers found that CBD promoted the increase of inflammatory-suppressor cells calledĀ myeloid-derived suppressor cells. The findings were reported in the study ā€œCannabidiol Attenuates Experimental Autoimmune…

Work Showing Potential of EHP-101 in MS Earns Research Award

Carmen Navarrete, PhD, has been granted a Scientific Innovation Award for her post-doctoral presentation suggesting that theĀ multiple sclerosisĀ (MS) treatment candidateĀ EHP-101Ā is anti-inflammatory and may boost remyelination,Ā Emerald Health PharmaceuticalsĀ announced. Navarrete, a senior scientist at Vivacell Biotechnology Espana, a company owned by Emerald Health Research, received the award at the…